Phillip Minar, MD, MS

Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. Matula, KA; Minar, P; Daraiseh, NM; Lin, L; Recker, M; Lipstein, EA. Health Expectations. 2022; 25:3105-3113.

Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis. Clarkston, K; Karns, R; Jegga, AG; Sharma, M; Fox, S; Ojo, BA; Minar, P; Walters, TD; Griffiths, AM; Mack, DR; et al. Journal of Crohn's and Colitis. 2022; 16:1735-1750.

Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Colman, RJ; Samuels, A; Mizuno, T; Punt, N; Vinks, AA; Minar, P. Inflammatory Bowel Diseases. 2022.

Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, J; LeLeiko, N; Shapiro, J; et al. Clinical Gastroenterology and Hepatology. 2022.

iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis. Daraiseh, NM; Black, A; Minar, P; Meisman, A; Saxe, M; Lipstein, EA. Patient Education and Counseling. 2022; 105:1628-1633.

Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn's Disease. Miller, TL; Schuchard, J; Carle, AC; Forrest, CB; Kappelman, MD; Adler, J; Ammoury, RF; Bass, D; Bass, J; Benkov, K; et al. Journal of Pediatrics. 2022; 242:86-92.e3.

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; et al. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.

Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Colman, RJ; Tsai, YT; Jackson, K; Boyle, BM; Noe, JD; Hyams, JS; D'Haens, GR A M; Van Limbergen, J; Rosen, MJ; Denson, LA; et al. Inflammatory Bowel Diseases. 2021; 27:1045-1051.

Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Hellmann, J; Etter, RK; Denson, LA; Minar, P; Hill, D; Dykes, DM; Rosen, MJ. Pediatric Quality and Safety. 2021; 6.